---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-035867"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2026-08-03T21:29:27+00:00"
generated_at: "2026-08-03T21:30:19.875697+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CFO Bradford Amman resigns; Roman Franklin appointed CFO via CFO Portal effective July 31, 2026

## Summary
- Amman receives 250,000 fully vested shares, option for 150,000 shares, and $13,333/month advisory fee for 180 days.
- Franklin's CFO Portal gets $324,000 annual retainer plus $237,360 equity award; Franklin receives option for 552,000 shares.
- Amman remains as transition employee for 90 days at $320,000 salary, then as independent contractor for 180 days.
- If Company raises $5M+ equity, Amman's outstanding payments accelerate and options fully vest.
- No disagreement cited; Amman reaffirms restrictive covenants and mutual releases exchanged.

## SEC filing metadata
- accession: 0001493152-26-035867
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2026-08-03T21:29:27+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315226035867/0001493152-26-035867-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315226035867/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-035867
- JSON: https://secwatch.observer/filing/0001493152-26-035867.json
- Plain text: https://secwatch.observer/filing/0001493152-26-035867.txt

## Key facts
- Executive change
  Roman Franklin was appointed as Chief Financial Officer at Vivos Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Effective July 31, 2026, the Board appointed Roman Franklin, age 42, as the Company’s Chief Financial Officer, and designated Mr. Franklin as the Company’s principal financial officer for purposes of the Securities Exchange Act of 1934, as amended.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716166/000149315226035867/0001493152-26-035867-index.htm
- Executive change
  Bradford Amman resigned as Chief Financial Officer and Secretary at Vivos Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer and Secretary
  source text: On July 31, 2026, Bradford Amman resigned as Chief Financial Officer and Secretary of the Company, and from all other officer and committee positions held by reason of his employment, effective as of that date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716166/000149315226035867/0001493152-26-035867-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.